FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148673802> ?p ?o ?g. }

• W2148673802 endingPage "838" @default.
• W2148673802 startingPage "831" @default.
• W2148673802 abstract "The aim of this study was to investigate the tolerability, pharmacokinetic interaction and antitumor activity of gefitinib (Iressa, ZD1839), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, combined with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced solid tumors.This was an open-label feasibility trial evaluating two doses of gefitinib (250 and 500 mg/day) in combination with gemcitabine and cisplatin. Gefitinib was administered daily from day 2 onwards. Gemcitabine 1250 mg/m(2) was given on days 1 and 8 and cisplatin 80 mg/m(2) on day 1 for up to six 3-week cycles. Patients could then continue to receive gefitinib monotherapy.Eighteen patients were entered, nine at each gefitinib dose level. Two patients developed dose-limiting toxicity: one grade 3 convulsion (250 mg/day dose group) and one grade 3 rash (500 mg/day dose group). The most frequently occurring adverse events in the combination phase were vomiting (17 patients), asthenia (16), nausea (14), diarrhea (14) and skin rash (13). The most common grade 3/4 adverse events were vomiting (seven patients), asthenia (six), thrombocytopenia (six), diarrhea (five) and anorexia (five). Pharmacokinetic analyses showed no apparent pharmacokinetic interaction between gefitinib and cisplatin or gemcitabine, with the exception of a possible small increase in the geometric mean exposure to gemcitabine seen on day 8 of therapy when given alone with the higher dose of gefitinib. Of 17 evaluable patients, nine had confirmed partial responses, seven had stable disease and one had progressive disease.Combination therapy of gefitinib with cisplatin and gemcitabine had a manageable and predictable safety profile, no major effect on exposure to any of the three drugs and antitumor activity." @default.
• W2148673802 created "2016-06-24" @default.
• W2148673802 creator A5000660231 @default.
• W2148673802 creator A5022063365 @default.
• W2148673802 creator A5022811952 @default.
• W2148673802 creator A5024897875 @default.
• W2148673802 creator A5025611128 @default.
• W2148673802 creator A5034169124 @default.
• W2148673802 creator A5035296183 @default.
• W2148673802 creator A5038204321 @default.
• W2148673802 creator A5044041856 @default.
• W2148673802 creator A5047771337 @default.
• W2148673802 creator A5089042997 @default.
• W2148673802 date "2004-05-01" @default.
• W2148673802 modified "2023-10-14" @default.
• W2148673802 title "Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors" @default.
• W2148673802 cites W1848316250 @default.
• W2148673802 cites W1995634658 @default.
• W2148673802 cites W2010174111 @default.
• W2148673802 cites W2021996848 @default.
• W2148673802 cites W2045993433 @default.
• W2148673802 cites W2057409901 @default.
• W2148673802 cites W2064047613 @default.
• W2148673802 cites W2080462767 @default.
• W2148673802 cites W2107595609 @default.
• W2148673802 cites W2110835998 @default.
• W2148673802 cites W2116538964 @default.
• W2148673802 cites W2126314379 @default.
• W2148673802 cites W2142661339 @default.
• W2148673802 cites W2167368130 @default.
• W2148673802 cites W2189849157 @default.
• W2148673802 doi "https://doi.org/10.1093/annonc/mdh188" @default.
• W2148673802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15111354" @default.
• W2148673802 hasPublicationYear "2004" @default.
• W2148673802 type Work @default.
• W2148673802 sameAs 2148673802 @default.
• W2148673802 citedByCount "48" @default.
• W2148673802 countsByYear W21486738022012 @default.
• W2148673802 countsByYear W21486738022013 @default.
• W2148673802 countsByYear W21486738022014 @default.
• W2148673802 countsByYear W21486738022015 @default.
• W2148673802 countsByYear W21486738022016 @default.
• W2148673802 countsByYear W21486738022017 @default.
• W2148673802 countsByYear W21486738022018 @default.
• W2148673802 countsByYear W21486738022019 @default.
• W2148673802 countsByYear W21486738022020 @default.
• W2148673802 countsByYear W21486738022021 @default.
• W2148673802 countsByYear W21486738022022 @default.
• W2148673802 countsByYear W21486738022023 @default.
• W2148673802 crossrefType "journal-article" @default.
• W2148673802 hasAuthorship W2148673802A5000660231 @default.
• W2148673802 hasAuthorship W2148673802A5022063365 @default.
• W2148673802 hasAuthorship W2148673802A5022811952 @default.
• W2148673802 hasAuthorship W2148673802A5024897875 @default.
• W2148673802 hasAuthorship W2148673802A5025611128 @default.
• W2148673802 hasAuthorship W2148673802A5034169124 @default.
• W2148673802 hasAuthorship W2148673802A5035296183 @default.
• W2148673802 hasAuthorship W2148673802A5038204321 @default.
• W2148673802 hasAuthorship W2148673802A5044041856 @default.
• W2148673802 hasAuthorship W2148673802A5047771337 @default.
• W2148673802 hasAuthorship W2148673802A5089042997 @default.
• W2148673802 hasBestOaLocation W21486738021 @default.
• W2148673802 hasConcept C121608353 @default.
• W2148673802 hasConcept C126322002 @default.
• W2148673802 hasConcept C143998085 @default.
• W2148673802 hasConcept C197934379 @default.
• W2148673802 hasConcept C2776694085 @default.
• W2148673802 hasConcept C2778375690 @default.
• W2148673802 hasConcept C2778570526 @default.
• W2148673802 hasConcept C2779438470 @default.
• W2148673802 hasConcept C2780258809 @default.
• W2148673802 hasConcept C2780580887 @default.
• W2148673802 hasConcept C2780852908 @default.
• W2148673802 hasConcept C71924100 @default.
• W2148673802 hasConcept C90924648 @default.
• W2148673802 hasConcept C98274493 @default.
• W2148673802 hasConceptScore W2148673802C121608353 @default.
• W2148673802 hasConceptScore W2148673802C126322002 @default.
• W2148673802 hasConceptScore W2148673802C143998085 @default.
• W2148673802 hasConceptScore W2148673802C197934379 @default.
• W2148673802 hasConceptScore W2148673802C2776694085 @default.
• W2148673802 hasConceptScore W2148673802C2778375690 @default.
• W2148673802 hasConceptScore W2148673802C2778570526 @default.
• W2148673802 hasConceptScore W2148673802C2779438470 @default.
• W2148673802 hasConceptScore W2148673802C2780258809 @default.
• W2148673802 hasConceptScore W2148673802C2780580887 @default.
• W2148673802 hasConceptScore W2148673802C2780852908 @default.
• W2148673802 hasConceptScore W2148673802C71924100 @default.
• W2148673802 hasConceptScore W2148673802C90924648 @default.
• W2148673802 hasConceptScore W2148673802C98274493 @default.
• W2148673802 hasIssue "5" @default.
• W2148673802 hasLocation W21486738021 @default.
• W2148673802 hasLocation W21486738022 @default.
• W2148673802 hasOpenAccess W2148673802 @default.
• W2148673802 hasPrimaryLocation W21486738021 @default.
• W2148673802 hasRelatedWork W1966884769 @default.
• W2148673802 hasRelatedWork W1974662648 @default.
• W2148673802 hasRelatedWork W1990407560 @default.

• next